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Abstract
This thesis describes the development of an objective motor score (OMS) of
Parkinson’s disease that utilizes the Quantitative Motor Assessment Tool (QMAT)
developed through efforts by the Intel Corporation and the Kinetics Foundation.
Parkinson’s disease (PD) is a movement disorder which is a member of a group
of neurodegenerative diseases marked by the depletion or impairment of dopamine-
producing cells in the brain. Since PD is chronic and degenerative, treatments are
intended to either improve the quality of life for sufferers by superficially treating
symptoms or slow and ultimately reverse the progression of the disease. No blood
test or biomarker exists, so current assessment of the disease relies on a subjective
tool called the Unified Parkinson’s disease rating scale (UPDRS) which is a coarse
scale that requires costly clinical administration and is subject to rater bias.
The objective motor score described in this thesis exhibits excellent clinimetric
properties, having demonstrated usability, validity, reliability, and responsiveness. It
was calibrated to the motor section of the UPDRS, but in addition to high correlation
with the motor UPDRS, it demonstrated an excellent ability to track deep brain
stimulation treatment levels and to detect improvement in motor function of subjects
due to dopaminergic treatment. With an excellent intraclass correlation coefficient,
the OMS is a reliable measure and due to the objective nature of the test, it does not
suffer from rater bias. Though these results come from the development phase, they
suggest that confirmatory studies will firmly establish the excellent properties of the
OMS.
i
While further studies are in motion to improve upon the sensitivity of the OMS by
exploring metrics of voice recordings and paced tapping tests, the OMS presented here
is a complete and usable tool for assessing the severity of PD-related symptoms. In
conjunction with the QMAT, it is ready to be used in clinical trials, clinical practice,
and even in the homes of patients who suffer from PD. This makes it an invaluable
tool that could begin to replace the UPDRS for use in PD research, reducing costs
and confounding factors in studies as well as extending their capabilities into the
home.
ii
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Chapter 1
Introduction
Parkinson’s disease (PD) affects between five-hundred-thousand and one-million Amer-
icans and perhaps four to five million people worldwide [1, 2]. The disease is primarily
characterized by four symptoms: tremor, rigidity, bradykinesia, and postural instabil-
ity. Though these symptoms present in varying degrees and combinations for different
individuals, they are chronic and degenerative, progressively worsening over time [1].
Tremor, the most often recognized symptom, refers to the trembling that can
affect the hands, arms, legs, and sometimes even the jaw and face. Rigidity, or
stiffness, often affects the limbs and the trunk. Bradykinesia is the term used to refer
to a general slowness of movement throughout the body. Finally, postural instability
refers to impaired balance and/or coordination [1].
PD is a member of a larger group of neuromotor diseases marked by the progressive
death of dopamine-producing cells in the brain. Dopamine is a neurotransmitter that
plays an essential role in the basil ganglia motor loop which is a critical part of
the brain’s control of the movement of the body. In addition to this, dopamine is
involved in parts of the brain that regulate emotion, motivation, and the feeling
of pleasure. This leads to a large range of non-motor symptoms of PD including
depression, anxiety, loss of energy, compulsive behavior, and many more. A root
cause of this loss of brain cells has been elusive and, as of yet, research has failed to
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produce a widely accepted explanation [1].
Though the exact number is very difficult to accurately determine, some studies
estimate that there are between five-hundred-thousand and one-million PD sufferers
in the United States alone, with about fifty-thousand cases diagnosed each year [1, 2].
Early stages do not necessarily reduce quality of life significantly, but as the disease
progresses it becomes increasingly difficult to perform everyday tasks and eventually
sufferers are completely invalid and bedridden.
A disease as common and debilitating as PD is a large burden to society due to
both medical bills and loss of productivity. The per patient cost has been estimated
at about $25,000 per year [2]. If the high estimate of one-million sufferers in the US
is accurate, then the annual burden of the disease for the country is about twenty-five
billion dollars [2, 3].
Especially in early stages, existing treatments can dramatically improve the qual-
ity of life. Two of the most common treatments are dopaminergic treatment and deep
brain stimulation (DBS). Both of these require a great deal of clinical monitoring and
adjustment. This can be difficult due to the lack of an efficient and responsive tool
for monitoring progression and severity of symptoms.
Because there is currently no known biomarker or blood test for PD, it is diagnosed
and monitored based on evaluation of the symptoms. Currently, studies involving PD
rely heavily on subjective rating scales [4]. These scales are often chosen to be the
primary outcome measures in clinical trials and thereby form the basis for deciding if
particular treatments have a significant effect when administered to groups with PD.
In addition to their use for measuring effects across subjects, the scores or subscores
from these scales are often used by physicians to help determine treatment type or
2
Chapter 1 Introduction
methodology and dosing for individual subjects.
Until the internal processes relating to PD are well understood and can be di-
rectly and conveniently monitored, physicians and researchers will have to rely on
indirect tests that make use of observations or measurements of the symptoms, most
notably the motor symptoms. This has led to much analysis and development of the
current standardized rating scales as well as an increase in research on objective mea-
sures that would make use of quantitative measurements of motor function utilizing
electromechanical devices [5].
Clinimetrics studies the properties of both rating scales and objective motor scores.
This is a science in development, rooted in the more established fields of psychometrics
and test theory [6]. It is concerned with the systematic validation of tests to be used
as neurological outcome measures. The minimum properties of such an outcome
measure, whether it be a rating scale or an objective motor score, are usability,
reliability, validity, and responsiveness [7]. A detailed discussion of these will be
given in subsequent chapters.
The Unified Parkinson’s Disease Rating Scale (UPDRS) has been called the “gold
standard” for quantifying the degree of impairment caused by Parkinsonian symp-
toms [8]. It is the most widely used standardized scale for assessing Parkinsonism [9].
A 2004 Movement Disorders Society critique stated that the strengths of the UPDRS
are wide utilization, application across the clinical spectrum of PD, nearly compre-
hensive coverage of motor symptoms, and clinimetric properties, including reliability
and validity [8]. After thorough review of cited studies relating to the clinimetric
properties of the UPDRS, the declaration that reliability and validity are among its
strengths appears to be an overstatement. Though many studies specify statistics
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that claim to demonstrate these properties, most often they are accompanied by
severe ambiguities along with vague interpretations.
Endeavors have been made to utilize electromechanical devices in obtaining use-
ful measures of PD. One of the most important studies with positive results came
from the simple use of a common midi keyboard. Termed Quantitative Digitography
(QDG), this method demonstrated an ability to distinguish between PD sufferers
and controls as well as patients in the “on” versus “off” state of medication. Though
the conclusions from this study were limited, they increased the hope that such an
objective measure might be developed and set the stage for further research [10].
Later studies demonstrated correlation between QDG metrics and the UPDRS
Part III score (Motor Section) as well a clear effect when comparing patients in
“on”/“off” medication states and “on”/“off” deep brain stimulation states [11]. Other
studies have made use of Timed Motor Tests and more specialized equipment such as
Motus, or Quantitative Repetitive Wrist Pronation-Supination (qr-WPS) which have
shown good results [12].
The Kinetics Foundation and Intel teamed together to create a self-contained test
battery based on active research in the area of objective PD measures. Initially known
as the At-Home Testing Device (AHTD), the hardware was renamed the Quantitative
Motor Assessment Tool (QMAT) and again renamed OPDM-Dexterity. This device
incorporated many tests that demonstrated promise in previous studies, including
pegboard, keyboard, button tapping, reaction time, voice, and tremor watch tests.
Christopher Goetz at Rush University led a feasibility study. This effort primarily
focused on proving that such a device could be successfully and easily used in the
home of patients and that the data gathered could be made available for analysis.
4
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Although the secondary goal of demonstrating validity of the test battery was initially
less successful, the feasibility and usefulness of such a device for at-home use was
clearly demonstrated [13].
As a consequence of this feasibility study, a cross-sectional study was created for
the primary purpose of establishing an objective motor score based on results from a
revised test battery implemented on the QMAT. The data obtained from that study
are the primary object of analysis for this research. This effort established an objective
motor score (OMS) utilizing an improved test battery on the QMAT. Initial analysis
demonstrated exciting properties of this OMS which suggest that such a motor test
could be an essential tool in the future research and treatment of PD. With a fixed
model created using the current data, the next step of analysis will utilize completely
independent data to clearly establish validity.
Although a validation phase is still necessary to firmly establish some of the clini-
metrics, this work took great pains to create an OMS which is very likely to possess
the necessary properties. The QMAT has shown usability in previous work and
the current test battery further established this, with patients reporting that they
are stimulated by the ability to track their own OMS results day by day. Analysis
showed good face validity, since the components present in the model reflect those
that showed promise in previous research [10]. High correlation with the UPDRS
motor scores substantiated convergent validity. Small changes between test-retest
scores demonstrated test reliability for both PD patients and controls. Most impor-
tantly, the effect size for “on”/“off” treatment and rank correlation with DBS power
levels demonstrated excellent responsiveness, reinforcing hope for strong performance
results on new data.
5
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Clinimetrics
The essential characteristics for an acceptable neurological outcome measure, such as
a rating scale or an objective motor score for Parkinson’s disease, are well documented.
These are components of the relatively new area of research called clinimetrics, the
development of which has relied heavily on the more established sciences of psycho-
metrics and test theory. The essential characteristics, or properties, can be broken
into four categories: usability, validity, reliability, and responsiveness [6, 7].
2.1 Usability
The term usability encapsulates the idea that an outcome measure cannot be pro-
hibitively expensive, time consuming, uncomfortable, or bulky. These qualities are
obviously subjective and depend on the context. A test that is considered usable in
a clinical trial at a medical facility would not necessarily be usable in the home. The
main point of specifying this essential characteristic is to remind test designers of
the fact that, regardless of the extent to which the other characteristics are met, an
outcome measure will only be valuable if it is practical and realizable. It also suggests
a criteria by which this factor could be used to decide on an appropriate outcome
measure from a set of similar choices.
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2.2 Validity
The concept of validity is a broad one which is typically broken down into three more
specific categories. These are content, criterion, and construct validity [6]. Although
these are related and may overlap one another to some degree, each is established by
unique processes of research.
Content validity is supported by logical arguments. One considers the question,
“Based on what is known, is it logical that this would be a valid outcome mea-
sure?” The answer to this comes from extensive research of literature, expert opinion,
qualitative patient interviews, and by examination of other measures of the same or
similar concepts. A test should be designed with content based on previous research
in related topics that have shown promise. It should also be reviewed by experts in
the field. Features that are generally agreed upon should be included and features
which lack a general consensus should be carefully studied and probably eliminated.
Feedback from patients should not be overlooked. If there are similar tests which are
used for the same or a similar concept, the overlap should be reflected by similarity
of content. Together, these steps are necessary to produce a test that the community
accepts and uses in practice.
Criterion validity refers to correlation of the proposed outcome measure with
an existing gold standard. In contrast with content validity which is established by
logical inspection, criterion validity requires a statistical relationship to be established
through quantitative assessment. In many cases, especially in the area of clinimetrics,
such a gold standard does not exist. In this case, one must rely more heavily on
construct validity to demonstrate overall validity.
Construct validity can be further broken down into four categories: 1) convergent
7
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validity, 2) discriminate validity, 3) group differences, and 4) hypothesis testing [7].
1. Convergent validity is similar to criterion; however, instead of requiring corre-
lation with a gold standard, correlation with other measures which attempt to
quantify or categorize the same or similar ideas must be established. If various
measures are highly correlated, then it may be said that they are converging
toward the same measure, establishing the fact that a single construct is being
measured.
2. Discriminate validity requires that a measure not be highly correlated with
something that it is not intended to measure. For example, if one is attempting
to quantify bradykinesia, or slowness, as a symptom of PD, one would expect
that this could be disambiguated from a difference in reaction time between
sexes. In other words, a measure of bradykinetic impairment should not be
highly correlated with gender.
3. Group difference refers to the ability of a test to demonstrate a difference be-
tween groups that are expected to have different levels for the construct of the
test. For example, a measure of the degree of impairment in Parkinson’s disease
ought to distinguish controls from PD sufferers.
4. Hypothesis testing requires that a measure support theoretical hypotheses which
are based on the construct that the test purports to measure. As an example,
PD is universally agreed to be degenerative. A measure of motor function,
therefore, should support the hypothesis that impairment is worse after two
years than at a baseline date.
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2.3 Reliability
For a test to have any value it must produce a consistent score when the underlying
construct is held constant. This concept is given the title reliability [6]. Two aspects
are generally considered. These are 1) internal consistency and 2) repeatability [7].
1. Internal consistency, or inter-item consistency, is the extent to which the various
elements that make up a test are measuring a single construct. It can be thought
of as the natural stability that the test has due to the structure of its content.
2. Repeatability refers to the quality of being able to produce a stable score when
a test is repeated under fixed or comparable conditions. Although this can be
decomposed in some detail, two important aspects are intrarater reliability and
interrater reliability.
(a) Intrarater reliability is the repeatability of scores given by a single rater or
device.
(b) Interrater reliability is the repeatability of scores given across raters or
devices.
2.4 Responsiveness
Responsiveness is the ultimate aim of any outcome measure [7]. It refers to the use
of a test to demonstrate significant differences. In PD, these could be differences
between the “on” and “off” states of dopaminergic treatment. Researchers believe
that deep brain stimulation (DBS) power level has a monotonic relationship with
PD impairment. An excellent demonstration of responsiveness, therefore, would be
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a monotonic relationship between the test score and the DBS power level. This
responsiveness is necessary to demonstrate any gradual reduction in symptoms or
slowing of degeneration.
2.5 Assessment of Clinimetrics
Usability does not have an accepted quantitative assessment methodology, and it is
unlikely that a reasonable standard could ever be established. There is no quantitative
assessment for content validity. It can only be confirmed by the consensus of experts
in the field. Because of this, it should be a part of the development process for an
outcome measure. Otherwise, much effort could be wasted in the development of a
test that never gains any acceptance.
To quantitatively assess criterion validity, a correlation coefficient is often used.
Pearson’s R is used if the measures are considered to have an approximately linear
relationship. Spearman’s rank correlation is used if a monotonic, though not necessar-
ily linear, relationship is considered more appropriate. Both of these statistics result
in a number between negative one and one, where negative one indicates a strong
inverse relationship, one indicates a strong direct relationship, and zero indicates no
correlation at all.
Assessment of the group differences criteria for validity can be done using the
concepts of sensitivity and specificity. These are binary operators that quantify a
measure’s ability to distinguish between two groups. Sensitivity, denoted here as φ,
assesses the ability of a test to positively identify subjects with the disability and
specificity, denoted here as θ, assesses the ability to correctly identify controls. These
10
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are defined by the following two equations:
φ =
NTP
NTP +NFN
θ =
NTN
NTN +NFP
where NTP, NFP, NTN, NFN stand for the number of true positives, false positives,
true negatives, and false negatives, respectively.
Ideally a measure’s sensitivity and specificity would both be one. For these to be
calculated, a threshold must be established for which scores falling below are identified
as “positive” and scores above are identified as “negative”.
Sensitivity and specificity may be combined to create a receiver operator charac-
teristic curve (ROC curve). This is a plot of sensitivity versus one minus specificity
(or, alternatively, the true positive rate versus the false positive rate). For a sam-
ple of PD subjects and controls, the threshold can be adjusted from the maximum
score to the minimum score obtained using the measure on all of the subjects. As
it is adjusted, the sensitivity will start out at a value of one and the specificity will
start out at a value of zero. Ideally, as the threshold increases the specificity will rise
to one before the sensitivity decreases. The ROC curve would be a flat line at one
and the area under the curve (AUC) would be one. This is equivalent to having the
highest control score below the lowest PD subject score. If, on the other hand, the
scores of controls overlap the scores of PD subjects, the sensitivity will drop before
the specificity rises to one, and the ROC curve will be somewhere below the flat line
at one and the AUC would be less than one. If the scores for both controls and PD
subjects are uniformly distributed across the same range, then the ROC curve will
11
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be approximately a diagonal line from the point (0,0) to (1,1), and the AUC would
approach one-half, indicating that the measure does not separate controls from PD
subjects at all. Thus, the AUC is a useful quantitative assessment of a measure’s
ability to separate groups.
Unless the test is always perfect in distinguishing PD and controls, AUC is not
independent of the sample that is taken. For example, if the sample of PD subjects
has advanced untreated symptoms and the controls are young and healthy, one would
expect high AUC, whereas if the PD subjects are in an “on” state and the controls are
age-matched, one would expect more difficulty in distinguishing the two groups and
therefore the AUC would be less than one. This is important to note when reviewing
research and when reporting results.
Analysis of reliability can be framed in terms of the following equation [14]:
S2X = S
2
T + S
2
E
where S2X is the variance of observed test scores, S
2
T is the variance of the true scores,
and S2E is the variance of the error between the observed test scores and the true
test scores. The square root of the error variance is often called the standard error
of measurement [14]. True test scores can be thought of as the expected score or
the mean score that would be obtained if the test was repeated many times without
any learning. Note that this error variance accounts for all sources of error including
characteristics of the test, the individual taking the test, and the test administrator.
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Reliability can then be defined as:
rXX′ =
S2T
S2X
In practice, Cronbach’s alpha or the intraclass correlation coefficient are often used to
estimate this reliability. Assessment of internal consistency is most often done using
Cronbach’s alpha. This can be expressed with the following equation:
α =
K
K − 1
(
1−
∑K
i=1 σ
2
i
σ2total
)
Cronbach’s alpha is given by α. K is the number of components, items, or questions
on the test. The variance of the ith component is σ2i and the variance of the total
score formed by summing the scores of all components is σ2total. Notice that if each of
the components is totally independent, then σ2total =
∑K
i=1 σ
2
i , and α = 0. Thus, total
independence corresponds with no internal consistency. However, if every component
is identical, then σ2total = K
2σ2i and
∑K
i=1 σ
2
i /σ
2
total = 1/K and Cronbach’s alpha takes
on the value of 1. Perfect correlation, then, corresponds to perfect internal consistency
as measured by Cronbach’s alpha [15].
One important point to consider when reporting or interpreting Cronbach’s alpha
is that the standard deviation of total scores, which depends on the diversity of the
group of subjects sampled, affects the estimate of internal consistency. For example, a
test may be made up of five identical metrics or components with additive independent
random error. Consider a group of subjects with identical impairments who take the
test. Notice that the differences in the value of test metrics, both between components
and between subjects, will only be due to the random error in the metrics. Thus,
13
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the five metrics will appear to be independent variables, σ2total =
∑K
i=1 σ
2
i , and the
estimate of Cronbach’s alpha will take on the value of 0. On the other hand, consider
a diverse group of subjects with a wide range of impairments taking the same test.
The difference in scores between components will have the same standard deviation;
however, the difference between subjects will reflect the differing impairment. Thus,
the metrics will be correlated, σ2total >
∑K
i=1 σ
2
i , and the estimate of Cronbach’s alpha
will be higher than 0. This demonstrates that the value of Cronbach’s alpha is
dependent, not only on the properties of the test, but also on the properties of the
sample group used to estimate internal consistency.
The statistic most often used for establishing intrarater and interrater consistency
suffers from this same problem. The intraclass correlation coefficient (ICC), here
denoted by ρ, is an estimate of the following ratio [16]:
ρ =
σ2between
σ2between + σ
2
within
where σ2between is the variance between objects of measurement, or subjects, and σ
2
within
is the variance within objects of measurement, that is variance between scores given
by the same rater at different times or different raters. Notice that as the variance
between subjects decreases and the variance within subjects is held constant, the ICC
decreases.
Like Cronbach’s alpha, the value of the ICC depends on the diversity of the
sampled group and has limited meaning without the specification of that group.
One article suggests that the closeness of the ICC of the motor UPDRS for a study
involving advanced PD to that of a study involving early PD sufferers confirms that
14
Chapter 2 Clinimetrics
the estimate is “correct” [17]. There are two necessary conditions required to make
this comparison valid. First, the distribution of motor UPDRS scores for the early
PD sufferers should have the same standard deviation as that of the subjects with
advanced PD. Second, the standard deviation of scores given by different raters or
by raters who repeated the tests at different times should be the same. A simpler
statistic that would characterize the reliability of a test score is the standard deviation
of scores for repeated tests.
Responsiveness can be expressed with a normalized effect size. The effect size of
a treatment is represented by the following equation:
∆ =
µ1 − µ2
σ
where ∆ is the normalized effect size, µ1 is the mean “on” treatment, µ2 is the
mean “off” treatment, and σ is the standard deviation of the sampled population.
Estimates of the standard deviation of the sampled population are made in various
ways, often using a pooled form [18]. This assessment of responsiveness is useful
for comparing medications’ effects on a single sample, but it does not generalize to
allow for comparisons of medications between studies and cannot be used to interpret
changes in score for an individual.
15
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Review of Literature
3.1 History of Rating Scales
After the first careful description of PD by James Parkinson in 1817 [19], little progress
in the study of the disease was made for some time. Treatments and symptoms were
explored, but the underlying causes remained undetermined until Carlsson’s studies
in the 1950s. He uncovered the biochemical changes in the brain which led to the
clinical practice of prescribing levodopa as the most efficacious treatment for PD in
1967. Since then, researchers have developed many more treatments. These include
surgical procedures, brain implants, medications, and physical therapy [1, 5].
To facilitate exploration of treatments, researchers studied methods for quantify-
ing the symptoms of PD. As early as the 1920s, doctors developed electrical and me-
chanical devices for monitoring motor function [20, 5]. At the same time, researchers
making efforts to evaluate the effects of treatments developed more subjective clini-
cal measurements. Some of these clinical scales remain in use, including Schwab and
England’s scale based on the estimate of percent ability of total activities of daily liv-
ing. A score of 100% indicated normal ability and 0% represented total helplessness.
Each 10% increment included a definition to help physicians place patients’ scores.
In 1967, Hoehn and Yahr introduced a scale intended to determine progression of
PD. This was a coarse scale with five defined stages ranging from early unilateral
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symptoms (symptoms occurring on one side) to symptoms causing inability to walk
at the last stage [20].
Many centers of PD research developed scores that quantified various symptoms
(e.g. bradykinesia, rigidity, posture, tremor, speech) with 3, 4, and 5 point scales.
From these scales, subscores could be calculated by grouping subsections together
and simply adding the scores. An overall score was calculated by a simple sum of
all of the subscores. Though many variants existed, important examples include the
Webster scale, the Columbia scale, and the UCLA scale [20]. Researchers primarily
needed these scales to evaluate the results of levodopa trials.
With various tools available for assessing specific symptoms as well as global
severity, different scores were used at different locations. Difficulty in comparing
results from study to study arose. This led to the suggestion that important features
of these existing scales be aggregated into a single rating scale which could be utilized
by everyone. Efforts culminated in the Unified Parkinson’s Disease Rating Scale
(UPDRS), completed in 1987 and described in detail in an article by Stanley Fahn et
al [20, 5].
3.2 Unified Parkinson’s Disease Rating Scale
The Unified Parkinson’s Disease Rating Scale (UPDRS) has become a primary tool
utilized by physicians and specialists in clinical trials, clinical practice, and other
research venues [9]. The most widely used section is Part III (Motor Examination)
which is comprised of 27 subscores that provide an estimate of the severity of the key
Parkinsonian motor symptoms. Because this scale plays such a significant role in PD
research, its clinimetric properties have been extensively studied. Although there are
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many good results, there are significant drawbacks and uncertainties which suggest
that the UPDRS Part III should be improved or, eventually, replaced [8].
The Movement Disorders Society has recently sponsored the development of a
revised version of the UPDRS called the MDS-UPDRS [21]. Some of the clinimetrics
properties of the new scale have been tested. Researchers concluded that the results
supported the validity of the scale as a replacement to the old UPDRS [22]. Since
this scale was first tested near the end of 2008, most current PD research still utilizes
the older scale. For this reason, the properties of the older scale will be discussed
here.
3.2.1 Usability
In many ways the UPDRS must be credited for being quite usable as evidenced by
widespread use [8]. The UPDRS requires no specialized devices. However, it requires
administration by a highly trained clinician, and it can only be completed in person.
Video allows for many parts to be scored, but elements such as the examination
of rigidity require the subject to be present. This not only causes problems for
administration, but also for the thorough testing of the reliability of the UPDRS.
3.2.2 Validity
Face validity was well established by the careful design of the UPDRS [20]. Satis-
factory convergent validity with other measures of PD has been suggested but not
quantified [23, 24, 25]. The construct validity of the UPDRS has been “suggested”
by various factor analyses of the UPDRS [23, 24, 25]. Finally, the sensitivity of the
scale is claimed based on the generalization that studies have demonstrated sensitiv-
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ity to change in clinical status. A detailed description of difficulty in establishing an
minimum clinically relevant difference is given without significant conclusions. Thus,
the major strengths of the UPDRS, aside from widespread acceptance, are not well
established [4].
One factor analysis revealed six clinically distinct impairments measured by the
motor UPDRS. These included three factors of bradykinesia, one for axial/gate and
two for the right and left sides, one factor for rigidity, and two factors for tremor, one
measured rest tremor and one postural tremor. Together, these six factors explained
78% of the total variation in the motor UPDRS for 294 patients, with the factors of
bradykinesia and rigidity alone accounting for 68% of the variation. The same study
demonstrated a high degree of internal consistency in the motor UPDRS (Cronbach’s
alpha, 0.95). This suggests that the motor section of the UPDRS gives a good single
measurement of overall impairment severity [24].
3.2.3 Reliability
The importance of interrater and intrarater reliability has been recognized by experts
in the field of PD, but it is difficult to characterize and estimate the degree to which
rating scales possess these properties. In spite of this, they are often cited as strengths
of certain rating scales.
In a 2003 Movement Disorder Society Task Force review of the UPDRS, reliability
and validity are cited as strengths. These claims are not well substantiated within the
report. Interrater reliability is vaguely described as appearing “adequate” according
to a few studies [23, 26, 27, 28]. However, a detailed look at these studies suggests that
the claims are not clearly supported and are not quantifiable or useful in the analysis
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of new results. The claim that intrarater reliability is a strength of the UPDRS is
also poorly substantiated with the statement that two studies showed “low to medium
intrarater reliability” [29, 28] and another demonstrated a high estimate of the ICC
[30, 4].
Statistics such as minimum clinically relevant difference and intraclass correlation
coefficient, though intended to communicate conceptually, actually screen important
results from studies. As an analyst trying to extract the information contained in
the score obtained for a particular rating scale and make inferences thereupon, a
simple report of the expected deviation between raters and within raters would be
much more valuable. These would provide a simple context for interpreting changes
in scores.
Fortunately, even though they have not been directly reported, some estimates
of the intrarater variability can be inferred from the results of a few analyses. From
one we can estimate the median absolute difference between scores given by a single
rater on repeated tests of 0.09×42 or about 3.8 points for patients in the “off” state
(mean motor UPDRS 42, standard deviation of about 13.25, ICC of 0.90) on the
UPDRS motor scale and 3.9 for patients in the “on” state (mean motor UPDRS
15.75, standard deviation of about 9.4, ICC of 0.89) [17]. The standard deviation
within raters, σwithin, can also be estimated from the ICC, again shown as ρ, using
the following formula:
σwithin ≈
√
σ2between ×
1− ρ
ρ
In the formula σ2between is the variance between subjects. The estimate of σwithin is
called the standard error of measurement [14]. This yields values of about 4.5 for
patients in the “off” state and about 3.5 for patients in the “on” state. The ICC can
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be used in the same way from a 2002 work by Siderowf et al. [30] to get a standard
deviation within raters for the UPDRS motor score of about 2.8. Note that this came
from a study of subjects with relatively low motor scores having a mean of 17.8, a
standard deviation of 8.4, and an ICC of 0.9. Finally, in a more recent study of a
sample of PD subjects with a mean UPDRS motor score of 19, a standard deviation
of 12, and ICC of 0.89, a value of 4.2 was obtained [31]. In one study this value is
reported directly as 2.48 [32]. Taking these examples together, one may infer that
the standard deviation of test scores when administering the UPDRS motor section
is somewhere between 2.5 and 4.5 points.
3.2.4 Responsiveness
There are examples of double-blind, placebo-controlled, randomized studies that have
used the UPDRS to demonstrate significant improvements with treatment as opposed
to with placebo [33, 9, 34]. In double-blind studies, neither the patients nor the raters
have access to treatment information. Treatment is generally randomized so that
levels do not depend on factors such as age, gender, and impairment level. When
the UPDRS motor subsection was used as an outcome measure, either a basic test
of significant change between mean “on” versus “off” medication or comparison of
change due to treatment versus placebo was made [33]. Results in the form of basic
tests of significance cannot be compared well to results using other motor scores to
evaluate the same treatments. They demonstrate validity more than responsiveness.
In a study of ELLDOPA treatment in early PD sufferers, researchers found that
after 24 weeks subjects treated with the medication decreased their motor UPDRS
by 26.2% versus a 4.0% increase (P ¡ 0.001) for those given placebo. In terms of
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raw UPDRS scores, those given ELLDOPA decreased their scores by 4.6 points and
those given placebo increased by 0.2 points [34]. The average person who received
treatment improved by an amount just about equal to the upper estimate of the
standard error of measurement described in Section 3.2.3. This means that for an
average individual the effect of levodopa could not be detected by the UPDRS.
3.3 Objective Measurement Tools
In the past several decades many researchers have focused on the development of
objective measures that circumvent the necessity for human raters to make a judg-
ment call when estimating the level of impairment for subjects suffering from PD.
Many attempts quantify differences in levels of impairment that are too subtle for a
human rater to distinguish. Countless examples utilize pegboards [35, 36, 37, 38, 39],
button tapping devices [40, 41, 42, 38, 39], torque and strain devices [43, 44, 12],
keyboards [45, 10, 43, 11, 44, 12], voice recorders, and accelerometers [41, 42, 12].
With these objective devices, measures have been developed in an effort to enhance
or even replace the clinical rating scales. Among these some of the most significant
results have come from button tapping devices, keyboards, and pegboard tests.
3.3.1 Button Tapping
Button tapping tests generally consist of at least two buttons placed adjacent to each
other. Two tasks are often defined. The first measures average movement time, or
tapping rate, by simply recording the number of taps alternating between two buttons
in a given period of time. The second measures reaction time by giving prompts at
unpredictable intervals and recording the amount of time lapsed between the prompt
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and the action of depressing the appropriate button following the prompt. In general
the measures of movement time tend to be significantly slower in PD sufferers than
in age-matched controls and often highly correlated with UPDRS motor scores.
One study compared the tapping speed of normal control subjects to that of
patients with PD. Two manual counters placed 20 cm apart tallied the number of
complete presses during a 1-minute trial. Differences between the averages of PD
subjects and controls tapping rate were clearly demonstrated. Significant correlation
between age and tapping rate was detected in normal controls. A learning effect was
consistent between dominant and non-dominant hands across controls and subjects
with PD [40].
A button tapping device was created to quantify button tapping pace, movement
time, and reaction time. Additionally, the Purdue pegboard test and UPDRS were
scored. Significant improvement in movement time and reaction time tests was shown
when comparing pre/post pallidotomy results for both contralateral and ipsilateral
hands [46].
The BRAIN TEST utilized a PC to implement an early description of an alter-
nating finger tapping test [47]. This computerized finger tapping test used the “s”
and “;” keys on a standard computer keyboard pressed alternately for a period of 60
seconds. Four metrics were evaluated, two of which demonstrated significant correla-
tion with the motor section of the UPDRS. Kinesia, simply the number of key presses
in the 60 second interval, performed the best with a Pearson correlation coefficient of
R = −0.69 (P ≤ 0.001) [45].
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3.3.2 Midi Piano Keyboard
A series of important studies has shown that the electronic midi piano keyboard may
be used as an effective objective measure of PD. In 2000 a group at the Department of
Neurology and Neurological Sciences at the Stanford University Medical Center inves-
tigated the use of a midi piano keyboard connected to a PC as an objective measure
of Parkinson’s disease. The study included 16 subjects with idiopathic Parkinson’s
disease in the “on” and “off” state of dopaminergic medication and also compared
results to a group of 11 age-matched controls. The test was named Quantitative
Digitography (QDG) and was used in several more studies at the Stanford Medical
Center.
The task was defined in a way that reflected the finger tapping task from the
UPDRS. Subjects were instructed to alternately press 2 keys with the index and
middle finger for 60 seconds with each hand. Blindfolds and headphones with white
noise eliminated visual and auditory feedback. Using a custom software, researchers
extracted 6 metrics from the key strikes of each test. These included the mean and
coefficient of variation (CV) of 1) downward velocity of strike, 2) duration of strike,
and 3) frequency of tapping.
Qualitative analysis suggested that normal subjects performed with a nearly con-
stant velocity, duration of strike, and frequency of tapping throughout the 60 second
test. They also performed without any apparent fatigue or hesitation and a rapid
rate of approximately 4 taps per second per finger and consistently with an average
CV of 9%. On the other hand, subjects with PD showed behaviors that could be
correlated with fatigue, tremor, freezing, and festination.
The quantitative results showed enormous promise, with every kinematic variable
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demonstrating a significant difference (P ≤ 0.05) between the “on” and “off” states
of dopaminergic treatment. Improvement was reported as the change in value from
the “off” to the “on” state divided by the “off” state value expressed as a percentage.
For the mean values, improvement was greatest for downward velocity, 196%, then
duration of strike, 47%, and finally frequency of tapping, 41%. The coefficient of
variation turned out to be an even more sensitive measure of improvement with the
CV of velocity improving an average of 229%, strike duration of 88%, and tapping
frequency of 68%.
In this group of subjects and age-matched controls a perfect classifier was iden-
tified to separate PD subjects in the “off” state of dopaminergic treatment from
age-matched controls. No subjects with PD in the “off” state scored lower than 30%
for CV of velocity, whereas no normal subject scored above the 30% threshold. This
suggested that a 60 second test measuring the CV of velocity might be used to iden-
tify PD sufferers. This measure, however, did not apply to PD sufferers in the “on”
state, though there was a significant difference in the average of frequency tapping
between those subjects and the age-matched controls [10].
A second study in 2005 utilized the same midi device and protocol to compare
QDG to the UPDRS motor test in evaluating improvement in fine motor control
from medication and deep brain stimulation. Although the test included 60 seconds
of repetitive alternating finger tapping (RAFT), the analysis used only the first 30
seconds. Again, six metrics were defined. These were revised from the original metrics
used in the 2000 study of QDG. They included key strike velocity, log of the duration
of finger strike, log of the interval between strikes, standard deviation of velocity,
log of the CV of duration of finger strike, and log of the CV of the interval between
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strikes.
The results showed that four of the six parameters studied were significantly cor-
related (P ≤ 0.05) with the UPDRS motor score. The strongest correlation was for
log of the CV of duration of strike (R = 0.66; P ≤ 0.001) followed by key strike
velocity (R = −0.61; P ≤ 0.001). Log of CV of the interval between strikes and log
of duration of the interval between strikes also correlated (R = 0.56; P ≤ 0.001 and
R = 0.50, P ≤ 0.01, respectively).
These factors also showed significant improvement during medication. Velocity
showed the most improvement from both dopaminergic and DBS treatment (P 
0.001). No patient had a worse velocity “on” medication than “off” and only one
had a worse velocity on DBS than off. Log of the interval between strikes and log of
the coefficient of variation of key strike duration both showed improvement as well
(P ≤ 0.001 and P ≤ 0.05, respectively).
A linear model, defined as the QDG composite score, fit a linear combination of
three of these parameters to the UPDRS motor score. The model included key strike
velocity, log of the interval between strikes, and log of the coefficient of variation of the
duration of strike. This model predicted the UPDRS motor score with a correlation
of r = 0.704 (P  0.001). As an example of the sensitivity of the QDG, the composite
score demonstrated a significant difference between treatments (P ≤ 0.05) even when
the UPDRS motor score was unable to distinguish the two (P = 0.08) [11].
Researchers also investigated the difference between therapies using each of the
six kinematic variables from the QDG and found significant differences in three out
of six of the variables. They found no difference for velocity or standard deviation of
velocity (P = 0.87 and P = 0.42, respectively) and no difference for interval between
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strikes (P = 0.08). They did, however, find significant differences in the duration
of strike and CV of the duration of strike as well as the CV of the interval between
strikes (P ≤ 0.05).
Though other factors seemed to be apparent in the raw data traces for both of these
studies, both concluded that the kinematic variables extracted from the QDG mainly
measured bradykinesia. Support for this conclusion came from high correlation of the
metrics with the bradykinesia subscore of the motor UPDRS [44].
A recent study included mean velocity of the key strikes from the more affected
side (MA) as a measure of fine motor bradykinesia in very early stage, untreated
PD. When compared to the performance of the non-dominant (ND) hand of age-
matched controls, a significant difference (P = 0.001) was once again found. This
further established the key strike velocity as an important tool that may be used for
distinguishing sufferers of PD from normal subjects [12].
3.3.3 Pegboard
Pegboard dexterity tests have also demonstrated strong performance as indicators of
symptom severity in PD. They measure several aspects of PD symptoms including
speed of movement, tremor, and ataxia, [39] relying on both speed and fine motor
control in the upper extremity. One study found that using test scores from their
version of a pegboard test as the primary outcome in a trial that evaluates dopamin-
ergic treatment could theoretically reduce the number of patients needed to 57% of
the number needed when using the motor UPDRS score [38].
The Purdue pegboard test is used in a broad range of applications in various
forms. It consists of two parallel columns of holes separated by a few centimeters.
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When prompted, subjects remove pegs from containers at the top of the board one
at a time and insert them into the holes, starting from the top and moving toward
the bottom. The test is typically scored as the total number of pegs placed in a given
interval of time. Research has demonstrated that the test provides a measure of finger
dexterity; however, some research cautions that care should be taken to ensure that
scores are reliable [36]. In spite of this warning, this pegboard test and closely related
variants have been studied as an objective measure of PD.
Research on unilateral pallidotomy in PD analyzed scores from the UPDRS, the
Goetz dyskinesia scale, and the Purdue pegboard test. Results from the pegboard
test were used to indicate that there is not significant improvement in contralateral
bradykinesia after pallidotomy.
Kraus et al. studied a variant of the Purdue pegboard test in which subjects were
instructed to move twenty-five pegs over a distance of 25 cm from one set of holes into
a corresponding set of holes. The movement time required was measured and results
were compared for PD and age-matched controls. A highly significant difference in
scores was found (P ≤ 0.0005) indicating that the test produced an effective measure
of PD symptoms [39].
3.3.4 Test Batteries
One study in the early nineties created an entire system for evaluating the impair-
ment of subjects with PD. This included devices for measuring muscle tone, tremor,
reaction time, and movement time. Peripheral devices for making these measure-
ments connected to a PC computer with custom software for providing calibration,
testing, and data analysis. Analysts compared results from PD sufferers to those of
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healthy age-matched controls and demonstrated significant differences for metrics of
mean horizontal and vertical displacement of accelerometers attached to the hands as
well as mean movement time between the buttons of a peripheral device. Significant
differences were also demonstrated in measurements of muscle tone as measured by a
torque sensing device attached to the wrist. Although researchers concluded that the
test was valid for clinical use in measuring tremor, muscle tone, and bradykinesia,
the test battery gained little traction [41].
3.3.5 At-Home Testing Device
Finally, in 2009, an article by Goetz et al. established the feasibility of a device de-
veloped in a highly collaborative effort. The at-home testing device (AHTD) was the
first fully self-contained tool for assessing PD symptoms using tests involving peg-
board, digitography, button tapping movement and reaction time, voice recordings,
and accelerometers for measuring tremor. Beyond the development of the device it-
self, a system for collecting and organizing data from research at clinics and in homes
was tested and validated.
Initially research focused on feasibility. Although validation of the device’s respon-
siveness to symptoms of PD was a secondary outcome, this aspect of the devices was
not established in the early research. Nonetheless, the capabilities of the devices were
modeled after much research that had taken place in individual objective measures,
and future validation was highly anticipated [13].
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3.3.6 Contributions of This Work
The work described by this thesis began the task of validating the AHTD as a useful
device for evaluating Parkinsonian symptoms. Furthermore, an objective motor score
was created which is ready to be used in clinical practice and clinical trials. To
accomplish these tasks, data from both the original feasibility study and from a new
cross-sectional study were analyzed.
The first step was to define a set of metrics and to extract them from the raw
data obtained from the studies. Clinimetric properties of these metrics were then
analyzed through statistics and visualizations. As a starting point for creating an
objective motor score, the design team decided on a linear model. Two reasons for
this decision were to reduce variability in the model selection process and to ensure an
interpretable model for evaluation by clinicians and experts in the field. By adjusting
parameters in the model selection algorithm, multiple models were obtained, and a
report was created which summarized the clinimetric properties of each model. In a
final review of this report, experts selected a model to be used as the objective motor
score.
From the design of the hardware platform, test batteries, and user interface to the
selection of the final model, this effort is the most thorough and rigorous approach
that has ever been taken to create an objective motor score. This OMS has been
implemented on a server that makes results available to authorized people via the
internet. Although there is plenty of room for improvement, the only task that
remains for the OMS to be usable as a primary outcome measure in clinical trials is
its full validation on new data.
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4.1 Hardware Platform
The QMAT device, developed by Intel, the Kinetics Foundation, and a consortium of
neurologists, is a self-contained testing apparatus (See Figure 4.1). Its dimensions are
10 inches by 6.5 inches by 2 inches and it weighs 10.2 pounds. A two-key keyboard
allows assessment of digitography or finger movement. Two buttons placed 173 mm
apart can record data from repetitive hand tapping. An eight peg pegboard test
assesses fine motor control of the hands. In addition to these onboard devices there is
a docking station for the Actiwatch Device (Cambridge Neurotechnology, Cambridge,
UK), a microphone port for voice recording, and an external foot tapper records data
from repetitive foot tapping tasks [13].
The upper panel contains an LCD screen for displaying instructions and examples
of the test requirements as well as a speaker for audio. Data is saved directly to a
USB storage device. Control buttons allow the user to access complete instructions
and to carry out all of the tasks from the test battery. [13]
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Figure 4.1: Illustration of the Quantitative Motor Assessment Tool.
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Task Dur. No. Total Description
(s) (s)
Finger Tapping 30 2 (LR) 60
Digitography 30 2 (LR) 60 Trill test with first and second fin-
gers. Called quantitative digitogra-
phy (QDG). Eyes closed, ears muf-
fled.
Reaction Time 30 2 (LR) 60
Peg Board 30 6 (LR) 120 Each hand only once.
Sustained Phonation 10 6 60 Ahhh. Normal and loud volumes.
Two repetitions of each. 48 kHz
sample rate.
Story 50 2 100 Subject reads three passages.
48 kHz sample rate.
Total 460 7.7 minutes for test time (excluding
directions).
Table 4.1: The above table summarizes all tasks included in the R1 test battery.
Note that the total time listed above does not include the time required to set up
the device, for the instructions to be given prior to each test, or for the data to be
uploaded to the server.
4.2 Test Batteries
4.2.1 Release 1 Test Battery
Because research originally focused on feasibility, the first test battery included tasks
that utilized each test type available on the QMAT device. Table 4.1 summarizes these
tests. With the algorithms for processing the voice tests unavailable, the preliminary
exploration of an OMS focused on metrics from the finger tapping, digitography,
reaction time, and pegboard tests.
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4.2.2 Release 2 Test Battery
The release 2 (R2) test battery was revised from the release 1 (R1) test battery with
several goals in mind. While keeping the test as brief as possible, all tests believed to
show any promise were to be included. Instructions for the test battery were to be
sufficient for the test to be self-administered. In the previous study, subjects did not
repeat the test and no controls were included to distinguish learning, boredom, and
disease progression. Both of these features were added to the cross-sectional study.
Because experts suggested that foot tapping might be a sensitive measure of PD
symptoms, engineers designed a foot pedal that took advantage of the microphone
port as an input. Test battery designers then added a foot tapping task for each foot,
augmenting the long list of motor tests and more completely covering the range of
tasks evaluated with the motor UPDRS.
The motor test battery was augmented by the foot tapping task. Table 4.2 lists
the names, time to complete, sides, and descriptions of each of the tasks in the R2 test
battery. To shorten the length of the test, only one of each motor task was included.
Analysis of foot tapping data was left out because of trouble with the use of the
foot tapping device, and analysis of the speech recordings was beyond the scope of
this initial study. Therefore, this analysis only covers the four motor tasks utilizing
the keyboard, pegboard, finger tapping, and reaction time tests of the QMAT device.
4.2.3 Release 3 Test Battery
In analysis of the foot tapping data, a lack of metrics with good performance combined
with complaints received from patients in the clinic led to the decision to eliminate
the foot tapping device completely. Patients also complained about the length of
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Task Dur. No. Total Description
(s) (s)
Foot Tapping 60 2 (LR) 120 Measured with a foot pedal. Based
on [2, 3].
Finger Tapping 60 2 (LR) 120
Digitography 60 2 (LR) 120 Trill test with first and second fin-
gers. Called quantitative digitogra-
phy (QDG). Eyes closed, ears muf-
fled.
Reaction Time 30 2 (LR) 60
Peg Board 30 2 (LR) 60 Each hand only once.
Sustained Phonation 10 4 40 Ahhh. Normal and loud volumes.
Two repetitions of each. 48 kHz
sample rate.
DDK speech 10 2 20 Puh-tuh-kuh. Two repetitions.
48 kHz sample rate.
Story 50 3 140 Subject reads three passages.
48 kHz sample rate.
Total 690 11.5 minutes for test time (exclud-
ing directions).
Table 4.2: The above table summarizes all tasks included in the R2 test battery.
Note that the total time listed above does not include the time required to set up
the device, for the instructions to be given prior to each test, or for the data to be
uploaded to the server.
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Task Dur. No. Total Description
(s) (s)
Finger Tapping 30 2 (LR) 120
Digitography 20 3 (LR) 120 Trill test with first and second fin-
gers. Called quantitative digitogra-
phy (QDG). Eyes closed, ears muf-
fled.
Peg Board 30 2 (LR) 60 Each hand only once.
Sustained Phonation 10 4 40 Ahhh. Normal and loud volumes.
Two repetitions of each. 48 kHz
sample rate.
DDK speech 10 2 20 Puh-tuh-kuh. Two repetitions.
48 kHz sample rate.
Story 50 3 140 Subject reads three passages.
48 kHz sample rate.
Total 540 9 minutes for test time (excluding
directions).
Table 4.3: The above table summarizes all tasks included in the R3 test battery.
Note that the total time listed above does not include the time required to set up
the device, for the instructions to be given prior to each test, or for the data to be
uploaded to the server.
the digitography tasks. Analysis of the data showed that metrics performed as well
on shorter segments of the data (20 to 30 seconds) as on the full length test (60 s),
leading to the decision to reduce the length of the test to 20 seconds. In addition
to shortening tests, repeated tests were added as a method for addressing the strong
learning effect detected in the R2 data. All of this led to the third test battery, release
3 (R3).
4.3 Metric Definitions
A general framework was established for developing metrics for all of the tasks. This
consisted of three steps.
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1. The raw data recorded during the tests yielded a vector of actions. For example,
the finger tapping tasks produced data with the following actions: right button
depressed, right button released, left button depressed, left button released.
Associated with each action was a time stamp, an action type, and a side.
2. Particular sequences of these actions were defined as events. Using the finger
tapping tasks as an example, the sequence right button depressed, right button
released, left button depressed, left button released, right button depressed was
defined as a cycle event. The time elapsed from the first action to the last action
was called the event duration and the time halfway between the start and finish
was called the event time.
3. Statistics for each sequences of event durations were calculated and these were
called metrics. Examples include the mean and standard deviation of the finger
cycle durations.
In analysis of the R1 and R2 data, both parametric and non-parametric statistics
were applied to these event durations and the resulting values were called metrics.
These included multiple measures of central tendency, variability, and trend. As part
of an effort to reduce the size of the metric pool, analysis in the R3 test battery
included only parametric statistics. The following metrics were chosen:
• Mean of event durations.
• Standard deviation of event durations.
• Coefficient of variation of event durations.
• Linear trend slope of event durations versus event times.
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Figure 4.2: Example of raw data obtained from the QMAT keyboard test. The red
and blue traces represent the relative key positions measured by the 20-stripe optical
encoder of each key. The light and dark gray patches represent the “dwell” and
“transition” events, respectively.
Because parametric and not robust statistics were used, a method of windowing called
Winsorizing [48] was applied to reduce the effects of outliers. Finally, to help control
the number of metric combinations, the metrics were calculated for both hands but
only the metric value from the hand with the worst performance was included.
4.3.1 Task Types and Event Definitions
Keyboard
For the keyboard an action corresponded to the detection of a key movement by an
optical encoder. For each action, the time stamp, key side, and direction of the key
movement (up or down) was recorded. A full downstroke produced 20 detections
by the optical encoder corresponding to 21 unique positions for each key. Using the
sequence of these actions, each key location relative to these 21 positions was tracked
through time.
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Using these actions, the following events were defined:
• Transition duration: the time elapsed during a sequence of movements of a key
up through the 3rd position and then back down through the 3rd position again.
• Dwell duration: the time elapsed during a sequence of movements of a key down
through the 18th position, and back up again through the 18th position.
• Cycle duration: the time elapsed during a sequence of movements starting from
the end of a transition event followed by a complete dwell event and finishing
with another complete transition event.
• Downstroke velocity: the distance traveled divided by the time elapsed in the
movement of a key from the 3rd position down through the 18th position.
Since the behavior of the index finger and the middle finger may more aptly show
disability, these event values were recorded separately for each finger and were also
combined into a set containing the values from both fingers.
Pegboard
Actions for the pegboard corresponded to the removal of a peg from a hole or the
insertion of a peg into a hole. For each action the hole number, an indication of
whether the action was an insertion or removal of a peg, and a time stamp were
recorded. Based on these actions, the following events were defined:
• Transition duration: the time elapsed between the removal of a peg and the
insertion of the peg on the opposite side.
• Dwell duration: the time elapsed between the insertion of a peg and the removal
of the next peg.
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Figure 4.3: Example of raw data obtained from the QMAT pegboard test. The red
and blue arrows represent the actions of removing or inserting a peg. The light and
dark gray patches represent the “dwell” and “transition” events, respectively.
• Cycle duration: the sum of a dwell duration and the following transition dura-
tion.
Finger Tapping
The finger tapping actions recorded the depression of a button or the release of a
button. For each action the button side, an indication of whether the button was
released or depressed, and a time stamp were recorded. Based on these actions, the
following events were defined:
• Transition duration: the time elapsed between the release of a button and the
depression of the opposite button.
• Dwell duration: the time elapsed between the depression of a button and the
release of that button.
• Cycle duration: the sum of a dwell duration and the following transition dura-
tion.
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Figure 4.4: Example of raw data obtained from the QMAT finger tapping test. The
red and blue arrows indicate actions of releasing or depressing the buttons on ei-
ther side of the device. The light and dark gray patches represent the “dwell” and
“transition” events, respectively.
Reaction Time
Actions recorded for the reaction time consisted of prompts, button depressions, and
button releases. For each action, three values were recorded. The first value indicated
whether the action was a prompt in the form of a beep, a left button action, or a
right button action. The next indicated whether the button was being depressed
or released. The last was a time stamp of the action. Based on these actions, the
following events were defined:
• Transition duration: the time elapsed between the release of the button and the
depression of the opposite button.
• Dwell duration: the time elapsed between a prompt and the release of the
button.
• Cycle duration: the sum of a dwell duration and the following transition dura-
tion.
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Figure 4.5: Example of raw data obtained from the QMAT reaction time test. The
black dots represent the beep from the audio speaker prompting the user to begin
moving to the opposite button. Red and blue arrows represent the actions of releasing
or depressing the buttons on either side of the device. The light and dark gray patches
represent the “dwell” and “transition” events, respectively.
4.3.2 Winsorizing
When appropriate, the metrics were Winsorized [48] to reduce the effects of possibly
errant outlying values. This is a simple windowing process in which any value below
a certain lower percentile is increased to the value of that percentile and any value
above a certain upper percentile is decreased to the value of the upper percentile. In
this case, a lower percentile of 3% and an upper percentile of 97% was chosen. Later,
the substitution of log values for the metrics eliminated the need for Winsorizing.
4.3.3 Choice of Hand
Instead of having a separate metric for each hand, metrics from the two hands were
combined into one by choosing the value from the side that showed the worst per-
formance. This was done for two main reasons. First, combining hands cut the size
of the metric pool from which a model was to be selected in half. For higher order
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models, in our case three metrics, this cuts the number of possible models approxi-
mately in half for each metric added. More specifically, for a three metric model, the
number of possible models is reduced by a factor of about 2× 2× 2 or 8. By making
the metric pool smaller, variability of the model selection process was reduced. Sec-
ond, this reduces the confusion of defining and tracking a dominant hand and a most
affected hand for each subject taking the test. This is important since many subjects
are ambidextrous and some do not demonstrate stronger Parkinsonian symptoms in
one side or the other.
4.4 Model Selection
4.4.1 Data
A data pair was defined as the data resulting from the completion of a QMAT test
battery combined with the UPDRS motor score taken within two hours. Misman-
agement of the R1 data resulted in the loss of a major portion of usable data pairs.
Originally, there were 50 PD sufferers who were to complete the QMAT test bat-
tery three times in the clinic. Appointments were scheduled at baseline, after three
months, and after 6 months. Ultimately, only 81 of the sessions were usable for model
building.
The cross-sectional study was designed to quickly generate a large data set which
was uploaded to a server for immediate analysis. In this way, test battery adjustments
were determined and implemented as the study progressed. The R2 test battery
included 108 data pairs taken by 57 PD sufferers and 19 age-matched controls. Data
screening reduced this to 92 data pairs taken by 51 PD sufferers and 17 age-matched
controls. 13 of the dropped data pairs resulted from incorrectly completed pegboard
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tests and 3 resulted from incorrectly completed keyboard tests. Thus, 73 PD and
19 age-matched control data pairs were available for analysis (including data pairs
obtained by subjects who repeated tests). Of these, 19 of the PD subjects took
repeated tests that could be used to study OMS reliability.
Initially predictors were selected from a pool that included 12 finger tapping, 48
keyboard, 12 pegboard, and 8 reaction time metrics. Only metrics from the keyboard
and pegboard tasks were selected by the stepwise process. Using all four tests resulted
in the loss of more data due to errors encountered in the reaction time and finger
tapping tests. Since the selection process ignored metrics from these tasks, the use of
the data could be maximized by dropping them from the metric pool. The remaining
pool included 48 keyboard and 12 pegboard metrics.
After an initial investigation of the R2 test battery data obtained in the cross-
sectional study, changes to the test battery were implemented and R3 was created.
A total of 302 R3 data pairs were collected. Due, presumably, to improvement to
instructions and in event extraction algorithms, only 9 data pairs had to be dropped.
Of these, 6 were due to unsatisfactorily completed keyboard tests and 3 were due to
unsatisfactorily completed pegboard tests.
The remaining 293 data pairs were taken by 38 PD sufferers who repeated the
test twice an hour apart, 23 controls who took the test each day for at least 4 days,
10 controls who took the test once, 6 PD subjects who took the test at varying levels
of DBS power, 12 PD subjects who took the test “on”/“off” medication, and 8 other
PD subjects who took the test once.
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4.4.2 Selection Algorithm
For each release, the model was chosen by a simple stepwise selection process. In
a series of steps, the model was augmented with a metric and the “leave one out”
correlation with the UPDRS motor score was calculated. The metric with the highest
value was tagged as a possible candidate for the model. Each metric was tested and
the one contributing the highest correlation was chosen for the model. Next, the
model was augmented with a second metric selected from the metrics remaining in
the pool. Again, if the correlation increased, the metric was tagged as a possible
candidate to be included in the model. The metric that increased the correlation of
the model by the greatest margin was then kept in the model. This was repeated again
until three metrics were included in the model. A model size of three metrics was
chosen based on previous investigations, appearing to be the best choice considering
the limited amount of data available.
4.4.3 Model Fitting
The selection algorithm produced a set of metrics that could be used to predict the
UPDRS motor score with high “leave one out” correlation. These still needed to be
combined into a single score. To create the objective motor score, a simple least-
squares fit of the metrics to the motor UPDRS was used to estimate the parameters
in the following linear model:
Motor UPDRS = β1X1 + β2X2 + β3X3 + ω
where Xi is the i
th metric, βi is the i
th parameter and ω represents a zero mean
Gaussian error term. After the parameters were estimated, an objective motor score
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was defined by the following equation:
OMS = b1X1 + b2X2 + b3X3
where the metrics are the same as above, but bi represents the least-squares estimate
of βi from the model above.
4.4.4 Performance Measures
The feasibility study that produced the R1 data did not include age-matched con-
trols, repeated tests, or “on”/“off” medication comparisons. Therefore, analysis was
limited to evaluating models’ correlation with the UPDRS motor score. Usability
and convergent validity were evaluated, but reliability and responsiveness could not
be considered.
More performance measures were available to be applied to the R2 OMS. Consid-
erations included face validity, correlation with the UPDRS motor score, reliability,
and the ability to distinguish PD from age-matched controls. Models were shown to
clinicians and other experts to determine if the metrics used made sense. Correla-
tion with the UPDRS motor score was evaluated based on the Pearson correlation
coefficient. The ICC was used to compare models’ reliability. Finally, the ability to
distinguish between PD and age-matched controls was measured by the area under
the ROC curve.
A more thorough examination of the R3 model was made possible by the diversity
of the R3 data set. Performance measures were available for validating an objective
motor score’s usability, validity, reliability, and responsiveness. Beyond the usability
already demonstrated by the feasibility study [13], total time for testing was consid-
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ered to improve usability. Again, the model was reviewed by experts to determine
if the metrics included in it made sense. Correlation with the UPDRS motor score
was used to demonstrate convergent validity. The area under the ROC curve and
comparison of means were used to evaluate validity based on the ability to separate
distinct groups. ICC and standard deviation between repeated tests were used to
demonstrate reliability. Effect size and comparison of mean “on” versus “off” OMS
were used to evaluate responsiveness.
4.4.5 Statistical Methods
Establishing statistical significance and confidence intervals for the results in this
report proved to be an unwieldy problem. Standard tests of significance and methods
for creating confidence intervals exist for Pearson correlation coefficient, intraclass
correlation coefficient, difference in means of both paired and unpaired samples, and
Spearman’s rank correlation coefficient. However, in general these methods require
that the samples are taken at random from the distributions involved. In this case the
entire data set is a random sample, but during the process of metric subset selection
and model fitting, bias was introduced and the resulting objective motor scores cannot
be considered random. Estimating the bias produced by the selection process is a
difficult problem.
Analysis of the UPDRS has shown that there are several relatively independent
factors which contribute to the overall score [25]. This reflects the fact that PD
itself is a multifaceted disease with symptoms of tremor, rigidity, bradykinesia, and
impaired balance and ambulation. Not only that, but the distribution of symptoms
between subjects varies to a great degree, so that some suffer more from tremor and
stiffness and others present stronger symptoms of bradykinesia [1].
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In calculating a large number of metrics, the intent was to capture signals which
were strongly related to as many of the symptoms as possible, and to find as small
a subset of metrics that would be sensitive to those symptoms. Unfortunately, too
many metrics increased the probability that a random sequence would be found that
appeared to be highly correlated with the UPDRS.
These two issues express themselves, mathematically, as characteristics of the
covariance matrix of the metrics augmented with the UPDRS motor scores. This
covariance matrix can only be estimated based on the samples. If too few metrics are
considered, then the multifaceted nature of the symptoms and their varying degrees
between subjects will be missed, resulting in a high value for the standard error in
estimating the UPDRS motor score. A covariance matrix with enough structure to
express these complicated relationships would require more metrics. However, a large
covariance matrix estimated using a relatively small number of samples has a high
probability of containing unrealistically strong relationships to the UPDRS motor
score.
Although some exploration of the structure of the covariance matrix and methods
for estimating the bias by a resampling method called bootstrapping was attempted,
the issue proved to be beyond the scope of this research. However, to give some sense
of the levels of significance and the confidence bounds on the statistics, standard
methods were applied.
Estimates of levels of significance (p-values) and a 95% confidence interval for
Pearson correlation coefficient between the OMS and the UPDRS motor scores were
based on the student-t test. The paired student-t test was also used for comparing the
difference in means of paired tests, including repeated tests and tests taken “on”/“off”
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of medication. For estimating the difference in the mean OMS for controls and PD
subjects, the two-sample student-t test was used. 95% confidence interval for ICC was
estimated based on analysis of variance [16]. To estimate the p-value of Spearman’s
rank correlation coefficient for OMS versus DBS power level, the exact permutation
distribution was used since the sample sizes were small. Finally, to estimate the 95%
confidence interval for the area under the ROC curve (AUC), a simple bootstrapping
resampling method was used [49].
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R1 Analysis
5.1 Results
Using the data collected under the R1 test battery, approximately 1200 metrics were
calculated. Note that there exist approximately 12003 or about 1.7 billion three met-
ric models. These included metrics distinguished based on dominant, non-dominant,
most affected, and least affected sides. Using this pool, the modified stepwise algo-
rithm selected the following model.
OMSR1 = 2.63 + 13.56X1 + 23.37X2 + 14.96X3
• X1 - Mean of the middle finger cycle durations, right and left hands combined
by maximum value, keyboard test
• X2 - Coefficient of variation of the index finger dwell durations, right and left
hands combined by maximum value, keyboard test
• X3 - Mean of the transition durations, right and left hands combined by maxi-
mum value, pegboard test
This data did not allow for extensive performance measures. In fact, no controls
or even repeated tests were available. This top model had a Pearson correlation
coefficient of about 0.70.
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Figure 5.6: Scatter plot showing the correspondence between the R1 OMS and the
motor UPDRS score for each of the R1 test sessions. Points falling on the diagonal
line have an equal OMS and motor UPDRS score.
5.2 Discussion
No metrics came close to showing the same correlation with the motor UPDRS as
the keyboard metrics, in particular the mean transition, dwell, and cycle durations.
This chapter includes these R1 results in order to explain the careful analysis done
on the R2 test battery.
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Figure 5.7: Mean key cycle duration demonstrated the most promise of any metrics
in the R1 test battery. Much of the R1 OMS correlation with UPDRS comes from
this single metric.
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R2 Analysis
6.1 Results
Using the data collected with the R2 test battery, the stepwise regression algorithm
selected the following model.
OMSR2 = −7.23 + 15.33X1 + 16.43X2 + 9.543X3
• X1 - Mean of the transition duration from the pegboard test, right and left
hands combined by maximum impairment value.
• X2 - Standard deviation of the middle finger transition durations from the
keyboard test, right and left hands combined by maximum impairment value.
• X3 - Coefficient of variation of the dwell duration from the pegboard test, right
and left hands combined by maximum impairment value.
6.2 Correlation With UPDRS
The correlation with UPDRS motor scores was much lower for this R2 model and
data set. The leave-one-out correlation value was only 0.52 and Pearson correlation
coefficient was only 0.60. Most of this correlation comes from the first metric (R =
0.52). This only explains about 25% of the variation in UPDRS motor scores.
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Figure 6.8: R2 objective motor score versus UPDRS motor score for PD sufferers.
Points for controls are shown in red and points for PD are shown in blue. Tests taken
one directly after the other are connected with a green line.
6.3 Ability to Distinguish PD Patients from Controls
Figure 6.8 shows the scatter plot of OMS versus UPDRS motor scores for subjects
who took the R2 test battery. In this case, some subjects took the test back-to-back.
The results from these two tests are connected with a green line. Also, the R2 data
included age-matched controls. Their results are shown in red. These fall on the left
side of the plot because their UPDRS motor scores were reported to be 0. With an
AUC of 0.89, highlighted in green on Figure 6.9, this model showed a remarkable
ability to distinguish controls from subjects with PD.
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Figure 6.9: Top left is the histogram of PD patients’ OMS. Bottom left is the his-
togram of control patients’ OMS. Right side shows the receiver operator characteristic
plot for distinguishing PD from control patients.
6.4 Repeated Tests
Though the AUC was high, this model demonstrated a very low ICC of only 0.31. In
Figure 6.8 the long green lines show large offsets between scores on repeated tests.
Figure 6.10 may explain this low ICC, showing a significant learning effect. On
average, scores were reduced by 2.81 OMS points from test 1 to test 2.
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Figure 6.10: Difference of R2 objective motor score for tests repeated one after the
other. Note that the histograms show the first test score minus the second test score
so that a significantly positive mean may imply a learning effect in the test battery.
6.5 Discussion
Results for the model selection and performance evaluation of an R2 OMS model fell
below that of the R1 model. Although in R1 the keyboard test produced the metrics
that showed the clearest correlation with the motor UPDRS, for R2 the only metrics
with the highest correlation came from the pegboard test. The need to understand
this loss of performance in the keyboard test led to a careful investigation of the data
obtained from the R2 test battery.
In Figure 6.11 a scatter plot of the mean key cycle duration versus motor UPDRS
is shown. Although correlation is low, one may observe many points with high mean
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key cycle duration and relatively low motor UPDRS scores. In general, patients with
low motor UPDRS ought to be able to perform the test more quickly; they clearly did
not. At the high end of the UPDRS, no subjects performed quickly. This results in
a somewhat triangular shape in the scatter plot. All subjects with high impairment
performed slowly, but subjects at lower impairments performed at a wide range of
speeds.
Figure 6.11: Mean keyboard cycle duration performed best among all metrics for the
R1 test battery; however, the performance was lost in the R2 test battery.
Looking deeper into the raw data for the keyboard tests, investigation uncovered
possibly important and somewhat unexpected characteristics of the tests. Figure 6.12
shows three unique strategies used by test takers to complete the keyboard test. The
first, 6.12a, shows the pattern described in the QMAT instructions. One key is
depressed and then fully released before the next key is depressed and fully released.
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The second, 6.12b, demonstrates another, faster method, where the subject begins to
depress the second key at the same time that the first key begins to raise. Though
this may appear to be an intuitive motion, it does not match the instructions and
gives the test taker an unfair advantage in speed over the person who correctly takes
the test. A third strategy, shown in Figure 6.12c, appears to use a single motion to
press both keys through a sort of rocking or galloping motion. This further increases
the speed of the test taker and confounds the use of “mean key cycle duration” as
a metric for impairment. Furthermore, some subjects actually changed strategies
partway through the test as demonstrated by Figure 6.13.
(a) Correctly (b) “Teeter-Totter” (c) “Gallop”
Figure 6.12: (a) Raw data from a subject who took the test according to the instruc-
tions, depressing a key and completely releasing before depressing the next. (b) A
different strategy where the subject began depressing a key at the same time that they
began to release the other. Note that the time scales are different and the so called
“teeter-totter” strategy is actually much faster. Finally, (c) shows a third strategy
resembling a “gallop.”
A second confounding factor in the keyboard test comes from the fact that different
patients with PD present with different impairment symptoms. Thus, some may be
fast but irregular, whereas some may be slow but very regular. These difference are
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Figure 6.13: This raw keyboard data example shows that a subject changed strategies
just over 13 seconds into the test.
demonstrated in Figures 6.14 and 6.15 with subjects who have about the same motor
UPDRS score.
The discovery of several unexpected results while examining the keyboard data
led to careful examination of the other tests from the R2 battery. Automatic reports
with visualizations were created for the purpose of validating incoming data from
each test as well as troubleshooting algorithms for automatically detecting events
and calculating metrics. These tools produced key learnings for all of the test types.
Most data lost in the automatic event detection and metric calculation algorithms
came from the pegboard. Visualizations allowed the source of these errant tests to
be evaluated. Most commonly, patients removed two pegs at once and inserted both
on the opposite side of the board. Also, patients commonly changed the order of the
peg movements, and occasionally placed pegs into improper holes. Figure 6.16 clearly
demonstrates this last behavior.
The finger tapping and reaction time tests utilized the same buttons. Visual
analysis of the tests led to the realization that patients confused the two tests at
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Figure 6.14: This subject’s impairment was mainly characterized by extreme slowness
of keystrokes.
Figure 6.15: Though this subject was able to perform the keyboard test relatively
quickly with their index finger, they were unable to consistently make full keystrokes
with their middle finger.
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Figure 6.16: During this test the subject placed the first three pegs correctly, but the
fourth peg was inserted, incorrectly, in the position of the first peg. This led to an
entirely different ordering of the pegs and resulted in invalid peg data, making the
OMS impossible to calculate.
times, exhibiting behavior during the finger tapping test that reflected the reaction
time test and vice versa. Figures 6.17 and 6.18 demonstrate this behavior.
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Figure 6.17: Though this data comes from a finger tapping test, it appears that the
subject pressed a few buttons before pausing for nearly 20 seconds. It is possible that
the subject confused the finger tapping test with the reaction time test, waiting for
a prompt to continue pressing buttons.
Figure 6.18: During the reaction time test this subject clearly did not wait for prompts
from the speaker, but continued to alternate between buttons as though they were
taking the finger tapping test. This continued for about 30 seconds before they
stopped to wait for a prompt.
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R3 Analysis
7.1 Results
7.1.1 Model Description
The objective motor score is a simple weighted sum of three metrics which is repre-
sented in the following equation:
OMSR3 = −13.45X1 + 16.87X2 + 5.485X3 + 82.2
where
X1 Log of the Mean of the downstroke velocities from both keys, right and left
hands combined by mean impairment value. From the keyboard test.
X2 Log of the Mean of the cycle duration, right and left hands combined by mean
impairment value. From the pegboard test.
X3 Log of the Mean of the transition durations, right and left hands combined by
mean impairment value. From the keyboard test.
The selection algorithm was based on optimization of the leave-one-out correla-
tion with the UPDRS motor score. A least-squares fit to the motor UPDRS scores
produced the final model parameters optimized to minimize the mean squared error
across the available data set. Since most subjects took the test at least twice, the first
and last test from each was used to fit the final model. The decision to use the first
and last test was made in order to maximize the use of the available data without
relying too heavily on any one subject. This final model resulted in a leave-one-out
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correlation with motor UPDRS of 0.71 and a least-squares correlation of 0.73 (95%
confidence interval: 0.63 to 0.80, P  0.0001) as well as a mean absolute prediction
error of about 6.21.
Figure 7.19 shows scatter plots of the objective motor score versus the UPDRS
motor score. Blue points represent the data used to fit the final model. They include
the first and last test from each subject with Parkinson’s disease. If a subject only
completed the test once, then that was also included as a blue point. When subjects
took the test more than twice, the extra points were not used for fitting the model.
Those extra points are shown in gray. In the few cases when a UPDRS motor score
was given to a control, that data was included in the figure as a red point. Finally,
pairs of points representing subjects who took the test back-to-back with no treatment
are connected with green lines.
The initial pool did not include the log metrics. Visual review of diagnostic
scatter plots of each of these metrics versus the motor UPDRS revealed nonlinear
relationship, especially at higher values of impairment. Though mild across this data
set, a loosely exponential relationship appeared in the duration as well as the velocity
metrics. The addition of log values for both the keyboard test and the pegboard test
resulted in better linear relationships with motor UPDRS and reduced the values of
outliers, thereby eliminating the need for Winsorizing. With log values added to the
metric pool, the model selection algorithm included all log values in the final model.
Table 7.4 shows significant statistics summarizing the performance of the R3 OMS.
The first column shows the Pearson correlation with motor UPDRS. The second shows
the mean absolute error. Note that this error should be compared to points on the
motor UPDRS since the model is calibrated to that scale. The correlation between
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UPDRS DBS On/Off Repeated Tests Separation
RP MAE RS ΘES s ∆12 ICC ΘROC xCS xPD
OMSR3 0.73 6.21 -0.69 5.35 1.44 1.00 0.94 0.86 16.7 25.9
X1(k) 0.65 6.89 -0.83 -45.64 1.26 -0.10 0.93 0.67 22.5 25.8
X2(p) 0.51 7.58 -0.76 1.42 1.38 1.41 0.88 0.90 18.5 25.8
X3(k) 0.50 7.50 -0.64 2.40 1.45 0.49 0.85 0.73 21.4 26.1
# Pts. 120 120 54 24 76 76 76 97 33 64
# Subjs. 64 64 6 12 38 38 38 97 33 64
Table 7.4: Model statistics based on 64 patients with PD and 33 controls.
the R3 OMS and the motor UPDRS can be seen in the scatter plot of Figure 7.19.
Column three shows the average Spearman correlation (or rank correlation) with
DBS power level for 6 subjects. This value is negative since the R3 OMS generally
decreases as the power level approaches 100% of the optimal value. Figure 7.21 shows
the results for each of the subjects. In all but one case, the Spearman correlation fell
between -0.90 and -1.
The fourth column shows an estimate of the effect size for dopaminergic treatment.
To make this calculation, the test/retest standard deviation was calculated from the
subjects who repeated the test in identical clinical states. Here, the effect size reports
the average change in R3 OMS from the “on” state to the “off” state divided by the
test/retest standard deviation. In Figure 7.25 one can see that the change in OMS
from the “on” state to the “off” state is positive in all but one case.
The next three columns summarize the results from subjects who repeated the
test battery while in a constant impairment state. The average standard deviation
between the first and second test is labeled s which is an estimate of the test-retest
standard deviation. To measure the learning effect, the average change in OMS from
test 1 to test 2 was calculated, labeled here as ∆12. Figure 7.20 shows a histogram
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of the change in OMS from test 1 to test 2 for all of the subjects who repeated the
test. Finally, the intraclass correlation coefficient is shown in the column labeled
ICC. In Figure 7.19, the green lines and boxes show the pairs of repeated tests used
to calculate these statistics.
Under the heading “Separation,” statistics summarize the ability of the OMS to
distinguish PD patients from age-matched controls. The first, labeled ΘROC, shows
the area under the receiver-operator characteristic curve (ROC) based on the first
test of each control and each PD patient. Next, xCS and xPD show the average R3
OMS for the control and the PD patients’ first test, respectively. Histograms of these
scores, along with the actual ROC curve, are shown in Figure 7.24.
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7.1.2 Correlation with UPDRS
Figure 7.19: Scatter plot of R3 objective motor score versus UPDRS motor score.
Blue points show the data used to fit the model. Grey points represent additional
deep brain stimulation data used to help assess performance. Red points represent
scores from controls. Tests taken one directly after the other are connected with a
green line.
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7.1.3 Repeated Tests
Figure 7.20: Difference of R3 objective motor score for tests repeated one after the
other. Note that the histograms show the first test score minus the second test score
so that a significantly positive mean may imply a learning effect in the test battery.
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7.1.4 OMS Versus Treatment Levels
Figure 7.21: R3 objective motor score versus deep brain stimulation treatment level.
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7.1.5 R3 OMS for Controls Across Five Days
Figure 7.22: R3 objective motor score versus test day for controls who repeated the
test battery once per day for a period of five days.
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7.1.6 Changes of R3 OMS for Controls Across Five Days
Figure 7.23: Difference from the average of R3 objective motor score versus test day
for controls who repeated the test battery once per day for a period of five days.
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7.1.7 Ability to Distinguish PD Patients from Controls
Figure 7.24: Top left is the histogram of PD patients’ OMS. Bottom left is the his-
togram of control patients’ OMS. Right side shows the receiver operator characteristic
plot for distinguishing PD from control patients.
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7.1.8 Change in R3 OMS in “on” versus “off” State
Figure 7.25: Scatter plot of R3 OMS versus UPDRS for subjects “on” versus “off”
medication. Tests completed by the same subject are connected with a green line.
7.2 Discussion
These results from applying the R3 model to data from the cross-sectional study
demonstrate excellent clinimetric properties in most of the important areas described
in literature.
7.2.1 Usability
With the usability of the R1 test battery and the QMAT device firmly established
by the feasibility study both in the clinical setting and at home, no further defense
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is required to establish this property in the R3 test battery. In fact, the R3 OMS
reduces the necessary tests to a very small subset of those in the R1 test battery.
Only two task types are required to generate an objective motor score for patients
and these can be completed in less than five minutes. Patients who have been given
the opportunity to use the device on a daily basis have praised it, even saying that
they looked forward to seeing their score each day.
7.2.2 Validity
Validity of the R3 OMS sits on firm ground. Content validity has been established
by the fact that metrics in the model reflect those found in early experiments with
a similar device [10]. Both downstroke velocity and mean cycle duration were deter-
mined to be strong metrics for distinguishing controls from PD patients in that study.
In addition to this, the equation for calculating the OMS is clearly understandable,
with simple metrics that have been reviewed and approved by experts in the field.
Although no gold standard exists for establishing criterian validity, construct va-
lidity is supported by every available measure. High correlation between the R3
OMS and the motor UPDRS score (R = 0.73, 95% confidence interval: 0.63 to 0.80,
P  0.0001) shows convergent validity. A significant difference of 9.17 (95% con-
fidence interval: 6.42 to 11.92, P  0.0001) OMS points between controls and PD
patients demonstrates an ability to detect group differences. The AUC value of 0.86
(95% confidence interval: 0.81 to 0.91, P < 0.0002) further demonstrates this prop-
erty. Hypothesis tests are supported for significant mean change of 5.34 points (95%
confidence interval: 0.594 to 10.09, P = 0.03) in R3 OMS for patients in the “on”
versus “off” state of dopaminergic treatment, with a mean “on” score of 29.6 and a
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mean “off” score of 34.9. Similarly, a significant difference of 23.1 (95% confidence
interval: 1.27 to 44.9, P = 0.041) was found between patients on 100% DBS versus
0% treatment, with respective mean values of 25.1 and 48.2.
7.2.3 Reliability
A high intraclass correlation coefficient of 0.94 (95% confidence interval: 0.89 to
0.97) suggests excellent reliability. More importantly, though, the very low standard
deviation for repeated tests of about 1.44 compared to the value estimated for the
UPDRS of 4 shows excellent reliability. A similar value of 1.0 for control subjects who
repeated the tests each day for five days further establishes this important property.
7.2.4 Responsiveness
Results for both “on”/“off” medication and DBS treatment levels provide strong
support for the most important clinimetric property, responsiveness. Of the nine
subjects who repeated the test in the “on” and “off” states, eight showed a decrease
in impairment going from the medicated state to the “off” state and the other showed
only a very small increase. For the six subjects that repeated the test at a sequence
of DBS treatment levels, four demonstrated an excellent monotonically decreasing
relationship with a Spearman rank correlation coefficient between -0.9 and -1 (P <
0.0001) between R3 OMS and DBS treatment level. Though the other two subjects
did not show significant correlation (P = 0.33 and P = 0.20), one decreased OMS
with increased DBS stimulation and the other remained nearly flat.
In comparing the responsiveness of the OMS to the UPDRS one can see that the
average change in OMS from the “on” to “off” state of levodopa treatment was 5.34
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points and the average for the UPDRS was about 4.6 points [34]. These are close, but
when considering the approximate standard deviation of repeated tests for the OMS
of 1.44 points from section 7.1.1 versus 4.5 points for the UPDRS from section 3.2.3,
it is clear that the change in OMS due to treatment is much more significant due
to the reliability of the test. Of course, this must be validated by a study utilizing
independent data.
7.2.5 Learning Effect
Compared to the strong learning effect detected in the R2 data, the R3 data showed a
much reduced effect. This may be a consequence of both the improved instructions on
the R3 test battery as well as the inclusion of practice tests, feedback, and repeated
motor tasks. Though a significant learning effect was still detected, as apposed to
the mean change in OMS from R2 of about 3 points, the change in OMS for subjects
who took the R3 battery only improved by 1.0 point (95% confidence interval: 0.26
to 1.73; P = 0.0093).
76
Chapter 8
Conclusions
8.1 Summary of Contributions
In summary, this thesis introduced a new tool created to precisely and efficiently
characterize the level of impairment of people suffering from Parkinson’s disease.
After describing the need and purpose for such a tool, a review of relevant literature
was made to lay the groundwork for the analysis. This included a discussion of the
current practice of using the UPDRS, related efforts to develop objective measures,
and the tools used for analyzing clinimetric properties.
An initial methodology was developed for creating the objective motor score, and
the results of applying this methodology to the R1 and R2 test battery were presented
and discussed. When unexpected results were obtained, a deeper analysis was carried
out and remedial adjustments were made to the test battery based on this analysis.
The R3 test battery did indeed exhibit improved properties and based on this test
battery, an objective motor score with good clinimetric properties was created.
8.2 Conclusions
The feasibility of the use of the QMAT device had been firmly established, but previ-
ous research had not demonstrated a practical method for using the data obtained to
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quantify the impairment of subjects with PD. This research has taken the next step
and helped to established a complete test battery along with a corresponding motor
score that is ready for use, both in the home and clinical settings.
This objective motor score is a significant contribution because it is an efficient,
precise, and simple to use tool for the assessment of impairment for people with
Parkinson’s disease. It is important because PD is an extremely widespread, costly,
and debilitating disease. The objective motor score presented here may serve to make
clinical trials of new treatments more efficient and effective. A major advantage that
it holds over current practice of using clinical rating scales is its reliability. Results
from this motor score will be directly comparable from study to study and year to
year. In this way it can aid in the development of new treatments and hopefully
someday a final cure for Parkinson’s disease.
Though this research was investigatory in nature and could have failed to produce
a valid measure, it should not be surprising that the results were successful. Many
resources and much research went into the design of the hardware device. It is based
mostly on earlier research that showed promise. For the first time, though, these
tests have been compiled into a single test battery which yields a motor score that
can be used for disease assessment, whether it be used for single measurements of
impairment or for tracking impairment longitudinally.
8.3 Recommendations for Further Work
The next step in the process is to completely validate the OMS by applying it to a new
independent data set and firmly establish its clinimetric properties. This could be
completed with a comparable study to that of the new MDS-UPDRS [22]. Although
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the OMS appears to possess good properties, and measures were taken to help ensure
this, its validity cannot be proved without a follow-up study. In addition to this, the
following actions, some already in progress, are recommended.
• New QMAT devices with an adjusted range of angular detection on the keys
have been fabricated. Adjustments will have to be made to the current algo-
rithms to allow the objective motor score to be calculated for these devices.
Further analysis of the advantages of this change should also be carried out.
• A new test battery, Release 4, has been implemented and data is being collected
at sites around the world. This test battery includes a paced-tapping test for
the keyboard, similar to one that has shown promise in a previous study [50].
New algorithms for extracting metrics using the new test are currently under
development.
• Since there is an identical keyboard and pegboard test in the R4 test battery as
that in R3, the R4 data should be considered to potentially validate the current
OMS.
• The analysis software could be improved. Interface to remedial tools, model
selection parameters, and automatic reports should be simplified and improved
for easier use and reduced opportunity for user error.
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